Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of once-daily oral orforglipron versus placebo in adults with overweight or obesity, with or without type 2 diabetes
CTR20252894Phase 3Active
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of orforglipron in obesity, Overweight, type 2 diabetes mellitus (T2DM), sponsored by Eli Lilly and Company. Started Aug 2025; status: active.
02
Drugs
orforglipron
03
Conditions
obesityOverweighttype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20252894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252894.